The Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom.
Immunobiology. 2013 Apr;218(4):570-8. doi: 10.1016/j.imbio.2012.07.006. Epub 2012 Jul 21.
Alternative macrophage activation is largely defined by IL-4Rα stimulation but the contribution of Toll-like receptor (TLR) signaling to this phenotype is not currently known. We have investigated macrophage activation status under Th2 conditions in the absence of the core TLR adaptor molecule, MyD88. No impairment was observed in the ability of MyD88-deficient bone marrow derived macrophages to produce or express alternative activation markers, including arginase, RELM-α or Ym1, in response to IL-4 treatment in vitro. Further, we observed no difference in the ability of peritoneal exudate cells from nematode implanted wild type (WT) or MyD88-deficient mice to produce arginase or express the alternative activation markers RELM-α or Ym1. Therefore, MyD88 is not a fundamental requirement for Th2-driven macrophage alternative activation, either in vitro or in vivo.
替代型巨噬细胞的激活在很大程度上是由 IL-4Rα 刺激定义的,但目前尚不清楚 Toll 样受体 (TLR) 信号对这种表型的贡献。我们研究了在缺乏核心 TLR 衔接分子 MyD88 的情况下,Th2 条件下的巨噬细胞激活状态。在体外,缺乏 MyD88 的骨髓来源巨噬细胞对 IL-4 治疗产生或表达替代激活标志物(包括精氨酸酶、RELM-α 或 Ym1)的能力没有受到损害。此外,我们观察到在从线虫植入的野生型 (WT) 或 MyD88 缺陷型小鼠的腹腔渗出细胞中,产生精氨酸酶或表达替代激活标志物 RELM-α 或 Ym1 的能力方面,WT 和 MyD88 缺陷型之间没有差异。因此,无论是在体外还是体内,MyD88 都不是 Th2 驱动的巨噬细胞替代激活的基本要求。